Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000, 90014, Oulu, Finland.
Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu, Finland.
Br J Cancer. 2018 Jul;119(2):213-219. doi: 10.1038/s41416-018-0136-4. Epub 2018 May 29.
Matrix metalloproteinase-8 (MMP-8) is a protease mainly expressed by neutrophils that cleaves numerous substrates, including collagens and cytokines. We have previously shown that serum MMP-8 levels increase in colorectal cancer (CRC) and correlate with distant metastasis. However, short follow-up in our prospective cohort did not enable survival analyses at the time of the first publication.
Preoperative serum MMP-8 levels were measured by immunofluorometric assay in 271 CRC patients and related to clinicopathological parameters, markers of systemic inflammation (modified Glasgow Prognostic Score, mGPS; serum levels of C-reactive protein (CRP), albumin and 13 cytokines), the density of six types of tumour-infiltrating immune cells and survival.
Increased MMP-8 levels associated with higher mGPS and higher serum levels of CRP and several cytokines, including IL-1ra, IL-7 and IL-8 (p < 0.001 for all). Serum MMP-8 negatively correlated with tumour-infiltrating mast cells (invasive margin: p = 0.005, tumour centre: p = 0.010). The patients with high-serum MMP-8 levels (>100 ng/mL) had poor cancer-specific survival, independent of tumour stage, grade, lymphatic invasion, patient age, BRAF VE1 immunohistochemistry, mismatch repair deficiency, Immunoscore and mGPS (multivariate HR 2.12, 95% CI 1.21-3.71, p = 0.009).
High-serum MMP-8 levels are associated with systemic inflammation and adverse outcome in CRC.
基质金属蛋白酶-8(MMP-8)是一种主要由中性粒细胞表达的蛋白酶,可裂解多种底物,包括胶原蛋白和细胞因子。我们之前已经表明,结直肠癌(CRC)患者的血清 MMP-8 水平升高,并与远处转移相关。然而,我们的前瞻性队列研究的随访时间较短,在首次发表时无法进行生存分析。
采用免疫荧光法检测 271 例 CRC 患者术前血清 MMP-8 水平,并与临床病理参数、全身炎症标志物(改良格拉斯哥预后评分、mGPS;血清 C 反应蛋白(CRP)、白蛋白和 13 种细胞因子水平)、六种类型肿瘤浸润免疫细胞密度及生存相关。
升高的 MMP-8 水平与较高的 mGPS 以及较高的 CRP 和几种细胞因子(包括 IL-1ra、IL-7 和 IL-8)水平相关(p<0.001 均为)。血清 MMP-8 与肿瘤浸润肥大细胞呈负相关(侵袭边缘:p=0.005,肿瘤中心:p=0.010)。血清 MMP-8 水平较高(>100ng/mL)的患者癌症特异性生存较差,独立于肿瘤分期、分级、淋巴浸润、患者年龄、BRAF VE1 免疫组化、错配修复缺陷、免疫评分和 mGPS(多因素 HR 2.12,95%CI 1.21-3.71,p=0.009)。
高血清 MMP-8 水平与 CRC 中的全身炎症和不良预后相关。